Our vaccine strategy therefore prioritizes sustained activation of tumor-specific CD8+ T cells through dual mechanisms: a) Circumvention of T cell exhaustion via epitope optimization, and b) Synergistic engagement of B cell-mediated antitumor responses. This evidence concerns the gene CD8A and neoplasm.